BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering

BioAge Labs, Inc.

Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.
Phase 2a cardiovascular trial planned 1H 2026; ophthalmology expansion with DME trial mid-2026.
Completed $132.3M follow-on offering in Feb 2026; cash $285.1M at Dec 31, 2025, sufficient through 2029.
FY2025: collaboration revenue $9.0M (vs $0); net loss $80.6M ($2.24/share) vs $71.1M ($6.63/share) in 2024.
APJ agonist programs advancing; IND filing expected by end of 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.